Date: 2011-06-02
Type of information: R&D agreement
Compound: small molecule modulators of a priority biological target
Company: Evotec (Germany) Active Biotech (Sweden)
Therapeutic area: Immune diseases - Cancer
Type agreement: R&D
Action mechanism:
Disease:
Details: Evotec AG has entered into a medicinal chemistry collaboration with Active Biotech AB, following the successful conclusion of a High Throughput Screening campaign to identify small molecule modulators of a priority biological target, selected by Active Biotech, involved in immune disorders and cancer. Based on excellent progress made using its state-of-the-art Screening Platform in 2010, Evotec will now apply its integrated medicinal chemistry platform to optimise initial screening hits with the aim of progressing into a lead optimisation programme.
Financial terms: Financial details were not disclosed.
Latest news: